Stocktoria

LEMAITRE VASCULAR INC LMAT

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2006-10-19 · LEI

LEMAITRE VASCULAR INC (LMAT) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.83% (safety: safe). FY2025 revenue was $249.6M at a 23.1% net margin.

Chart by TradingView
84/100
Stocktoria Quality Score · grade A
6/9
Piotroski F — financial health
8.18
Altman Z″ — distress risk · safe
0.9%
Dividend yield 5y avg · safe · Dividend payout 31.4%
-2.6
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
7 5 3 2 3 7 3 7 5 6 2016201720182019202020212022202320242025
Altman Z″
11.06 12.30 11.38 8.09 5.73 11.37 11.15 11.31 7.56 8.18 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$82.13 as of 2026-08-01 · -13.9% 1y
$81.10$109.7552-wk

Beneish M-score: -2.6 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$2.2B
P / E37.9×
Dividend yield 5y avg0.9%
Net margin 5y avg17.8%
Return on equity 5y avg11.2%
Beta0.52
Employees646

Analyst price target

$118.75 +44.6% vs last
consensus: buy · 8 analysts
target range $102.00 – $135.00 · median $120.00
2 strong buy · 3 buy · 4 hold
Recent analyst actions
DateFirmRating
2026-06-03Barrington ResearchOutperform (main)
2026-05-06Barrington ResearchOutperform (main)
2026-05-06CitizensMarket Outperform (main)
2026-05-06Wells FargoEqual-Weight (main)
2026-02-26Barrington ResearchOutperform (main)
2026-02-26Roth CapitalBuy (reit)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net sold -$5.0M on the open market · 2 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 78%
Net marginstronger than 94%
Return on equitystronger than 82%
Revenue growthstronger than 71%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.702
Retained earnings / assets0.3
EBIT / assets0.11
Equity / liabilities1.771

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
LMATLEMAITRE VASCULAR INC6/98.1837.9+13.5%
KIDSORTHOPEDIATRICS CORP4/92.67+15.4%
CERSCERUS CORP4/9-13.54+16.1%
TMCITREACE MEDICAL CONCEPTS, INC.2/9-1.79+1.6%
SIBNSI-BONE, Inc.6/91.52+20.2%
SKINSkinHealth Systems Inc.6/9-1.89-10%
PRCTPROCEPT BioRobotics Corp3/92.18+37.2%

All Manufacturing companies →

About LEMAITRE VASCULAR INC

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

FAQ

Is LMAT financially healthy?

LEMAITRE VASCULAR INC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does LMAT pay a dividend, and is it safe?

Yes. LEMAITRE VASCULAR INC pays a dividend yielding about 0.83% with a 31.4% payout ratio, rated “safe” for safety.

How profitable is LMAT?

In FY2025, LEMAITRE VASCULAR INC had a net margin of 23.1% and a return on equity of 14.7%.

Is LMAT overvalued or undervalued?

LEMAITRE VASCULAR INC trades at about 32.6× trailing earnings — below its 10-year norm (10-year range 21.1×–50.7×, median 41.3×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for LMAT?

The average Wall-Street price target for LEMAITRE VASCULAR INC is $118.75, about 44.6% above the recent price, from 8 analysts (consensus: buy).

Is LMAT a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on LEMAITRE VASCULAR INC: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 37.9×, a dividend yield of 0.83%. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.